Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00411-9/fulltext?dgcid=hubspot_email_conferencealerts_ecfs25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--db-Xfczg_GQZATAbTsv0oz_uUZ5B_5jzNgaSgwTxZZksZN-0r61KSXS-oCHGKaK19k0I6DSahMEFZONDlJv0N6sSyEg&_hsmi=363829782&utm_content=363829782&utm_source=hs_email